Tissue Regeneration Technologies (TRT) has received notification from the US Internal Revenue Service (IRS) that it was approved to receive a $244,000 grant for the investment in nonbacterial prostatitis and cancer therapeutic discovery projects involving TRT's SoftWave technology.
The biological effects of SoftWave therapy include increased permeability of cell membranes, increased blood flow through angiogenesis, up-regulation of growth factors, and stem cell activation, and also proved beneficial to non-bacterial prostatitis and cancer therapy.
The US Department of Health and Human Services (HHS) has determined that the project met the definition of a ‘qualifying therapeutic discovery project’ and the IRS certified the qualifying investment and approved the amount of $244,000.
TRT’s research intends to identify how SoftWave technology aids intracellular communication and enhances the delivery of cancer fighting medications through increased cell permeability.
TRT CEO John Warlick said that nonbacterial prostatitis remains the most common but least understood form of prostatitis – clearly an unmet medical need that they wish to address with SoftWave therapy.